九芝堂(000989.SZ)：国际市场方面,吉象隆以出口GLP-1类药物(司美格鲁肽、替尔泊肽)为主

Core Viewpoint - The company Ji Xiang Long is leveraging downstream formulation demand to boost sales of upstream raw materials and chemicals, benefiting from the market opportunities created by the expansion of medical insurance coverage [1] Domestic Market - Ji Xiang Long is driving sales of raw materials and chemicals by relying on the demand from the downstream formulation sector [1] - The company is enjoying market dividends from the expansion of medical insurance in the domestic market [1] International Market - Ji Xiang Long primarily exports GLP-1 class drugs (Semaglutide, Tirzepatide) and has obtained DMF registration [1] - The company has not yet received FDA certification as it has not applied for formulation-related approval, thus it is currently exporting in the form of chemicals [1]